MorphoSys AG has drawn up a broad development plan for its newly authorised antibody therapeutic Monjuvi (tafasitamab) which, if successful, would see the drug investigated for a number of B cell malignancies. Monjuvi was approved by the US Food and Drug Administration on 31 July in combination with lenalidomide for the treatment of diffuse large B cell lymphoma (DLBCL). The approval marked an important milestone for the German company which is now a fully integrated biopharmaceutical enterprise.
